KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Other Non-Current Assets (2016 - 2026)

NovoCure's Other Non-Current Assets history spans 13 years, with the latest figure at $11.2 million for Q1 2026.

  • On a quarterly basis, Other Non-Current Assets fell 22.67% to $11.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $11.2 million, a 22.67% decrease, with the full-year FY2025 number at $10.6 million, down 27.51% from a year prior.
  • Other Non-Current Assets hit $11.2 million in Q1 2026 for NovoCure, up from $10.6 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for NVCR hit a ceiling of $15.6 million in Q2 2025 and a floor of $10.6 million in Q4 2025.
  • Historically, Other Non-Current Assets has averaged $12.6 million across 5 years, with a median of $12.2 million in 2024.
  • Biggest five-year swings in Other Non-Current Assets: surged 33.71% in 2023 and later fell 27.51% in 2025.
  • Tracing NVCR's Other Non-Current Assets over 5 years: stood at $11.2 million in 2022, then grew by 25.63% to $14.0 million in 2023, then increased by 4.25% to $14.6 million in 2024, then dropped by 27.51% to $10.6 million in 2025, then rose by 5.7% to $11.2 million in 2026.
  • Business Quant data shows Other Non-Current Assets for NVCR at $11.2 million in Q1 2026, $10.6 million in Q4 2025, and $12.4 million in Q3 2025.